Facts figures and features conference report / CONFERENCE: CROSS-BORDER ITALY-SLOVENIA BIOMEDICAL RESEARCH: ARE WE READY FOR HORIZON 2020?

Progetti finanziati nell’ambito del Programma per la Cooperazione Transfrontaliera Italia-Slovenia 2007-2013, dal Fondo europeo
di sviluppo regionale e dai fondi nazionali.
Projekti sofinancirani v okviru Programa čezmejnega sodelovanja Slovenija-Italija 2007-2013 iz sredstev Evropskega sklada za
regionalni razvoj in nacionalnih sredstev.
1
FACTS

FIGURES

FEATURES

Sabina
Passamon+

University
of
Trieste

Lead
Partner
of
Trans2Care

2
WHY
THIS
CONFERENCE?

•  Six
projects
with
44
different
partners
have
received
8.48

MLN
€
from
the
Cross-‐Border
Coopera+on
Programme
Italy-‐

Slovenia
2007-‐2013.

•  For
the
first
+me,
researchers
have
met
to
share
their
results

and
future
perspec+ves:

–  What
are
the
results
of
this
investment?

–  Will
new
scien+fic
knowledge
produce
any
technological
innova+on?

–  Is
there
any
benefit
for
our
quality
of
life
and
health?

–  Are
these
researchers
ready
to
successfully
compete
in
Horizon
2020

calls?

Read
more
in
the
Conference
flyer:

hp://it.trans2care.eu/UserFiles/file/
CBISBR_02_2014_full_programme_CMYK.pdf

3
FACTS

1.  Wish
to
share
what
we
do
in
our
cross-‐
border
projects

– objec+ves,
results,
vision

2.  Immediate
agreement
to
meet
at
this

Conference

3.  An
open
event

– other
colleagues
have
been
invited
to
the

Conference

4
FIGURES
of
arac+on
è
n
of
registra+ons

The
growing
curve
of
registra+ons:

up
to
181
on
the
day
of
the
Conference

5
The
geographical
origin
of
the
par+cipants

FIGURES
of
arac+on
è
not
just
a
local
event

6
FIGURES
of
arac+on
è
traﬃc
on
the
web

686
visualisa+ons
of
the
Conference
announcement

7
FIGURES
of
arac+on
è 65
posters

evaluated
for
their
Technolgy
Readiness
Levels

hp://www.ﬂickr.com/photos/trans2care/sets/72157641645322424/with/12830151975/

8
UniversiIes

48%

Research

Centers

19%
Hospitals

5%

SMEs

9%

Other

19%

Where
do
the
181
parIcipants

work
?

9
Where
do
researchers
come
from?

0" 2" 4" 6" 8" 10" 12" 14"
ELETTRA"
LNCIB"
AREA"
NIB"
INFN"
KI"
ZTM"
CBM"
Research(centers(
N"
0" 5" 10" 15" 20" 25" 30" 35" 40"
Trieste"
Primorska"
Udine"
SISSA"
Nova"Gorica"
Rijeka"
Ferrara"
Venezia"
Verona"
Universi(es)
N"

10
That’s
the
new
FEATURE
of
this

Conference
!

The
new
language
of
TRL

•  Understood
by
industries

•  Understood
by
H2020
evaluators

•  Understood
by
venture
capitalists

•  Understood
across
disciplines

Progetti finanziati nell’ambito del Programma per la Cooperazione Transfrontaliera Italia-Slovenia 2007-2013, dal Fondo europeo di sviluppo regionale e dai fondi nazionali.
Projekti sofinancirani v okviru Programa čezmejnega sodelovanja Slovenija-Italija 2007-2013 iz sredstev Evropskega sklada za regionalni razvoj in nacionalnih sredstev.
11
T.R.L. ASSESSMENT
FINAL REPORT
Dott. Adriano SAVOINI - T&B
e
associa+
Srl
Trans2Care Project Manager
TRL Evaluation Team Coordinator
Team members:
http://it.trans2care.eu/UserFiles/file/whoswhooftheconference.pdf

12
T.R.L. ASSESSMENT RESULTS
0
5
10
15
20
25
1 2 3 4 5 6 7 8 9 N/A
N.posters
TRL

13
CONCLUSIONS / COMMENTS
•  Most technologies need (much)
further development to be ready for
market (average TRL is 3)
•  (Apparently) few links with Industry
•  4-5 techs seem very promising for
market deployment
•  N/A = Not applicable; clinical studies,
presentation of the Institute, etc.

14
Can
this
analysis
be
independently

conﬁrmed?

•  Let’s
browse
the
“Bibliometric
analysis
of
ongoing

projects-‐Innova+ve
Medicines
Ini+a+ve
Joint

Undertaking
–
Report
2013”

•  We
can
see
how
many
collabora+ons
involve
public

research
ins+tu+ons
and
industries.

Read
more
in
hp://www.imi.europa.eu/sites/default/ﬁles/uploads/documents/
IMI_BibliometricReport_3.pdf

15
?

GO
TO
PAGE
57

OF
THE
IMI

REPORT

16
Pioneers
needed
!

for
smart
biomedical
industrialisa1on

It
appears
that
Italy-‐Slovenia
Cross-‐border

biomedical
researchers
are

not
involved
in

collabora+ve
research
projects
and
networks
of

industrial
and
academic
experts
supported
by

Innova+ve
Medicine
Ini+a+ve

17
Can
the
Cross-‐border
biomedical

research
community
provide
the

pioneers
?

for
smart
biomedical
industrialisa1on

Let’s
analyse
the
results
of
our
pre-‐conference
survey

62
respondents
out
of
ca.
160
registraIons

18
The
occupa+onal
proﬁle
of
par+cipants

Permanent(
30%(
Temporary(
70%(
What(kind(of(job(contract(do(
you(have(?(
YES$
35%$
NO$
65%$
Does%the%CBC%Programme%Italy2
Slovenia%200722013%fund%your%
contract?%
25#$#30#
29%#
31#$#36#
30%#37#$#43#
11%#
44#$#54#
24%#
55#$#70#
6%#
How$old$are$you$?$

19
i)
Clear
ideas
(turquoise
bars)

ii)
To
be
a
researcher
(blue
bars)
or
an
employee
(red
bars);

ii)
Not
to
be
an
employer
(green
bars)

Research(
Enterprise,(as(employee(
Enterprise,(as(employer(
Other(
No(idea(
0,0(
10,0(
20,0(
30,0(
40,0(
50,0(
60,0(
70,0(
unlikely( poorly(
likely(
fairly(
likely(
likely(
most(
likely(
9,5$
22,2$
50,8$
30,8$
21,2$ 26,9$
19,2$
1,9$
57,1$
4,1$
20,4(
26,5(
6,1(
66,7(
7,1(
%$
What$do$you$plan$for$your$next$job$?$
Research(
Enterprise,(as(employee(
Enterprise,(as(employer(
Other(
No(idea(
The
vision
of
the
par+cipants:

20
i)
First
choiche:
to
work
at
home
(red)

ii)
Second
choice:
to
work
close
to
home
(blue)

iii)
Third
choice:
to
work
abroad

In#the#Italy*Slovenia#Programme#Area#
In#your#country#
Abroad#
0,0#
10,0#
20,0#
30,0#
40,0#
unlikely# poorly#
likely#
fairly#
likely#
likely# most#
likely#
22,2# 12,7#
28,6#
19,1#
17,5#
1,7#
10,3#
20,7#
29,3#
37,9#
38,9#
18,5#
20,4#
14,8#
7,4#
%#
Where#do#you#plan#to#work#in#the#near#future#?#
In#the#Italy*Slovenia#Programme#Area#
In#your#country#
Abroad#
The
vision
of
the
par+cipants:

21
WHAT
NEEDS
TO
BE
IMPROVED

•  More
connecIons
involving
reasearchers,
industries

and
public
bodies

•  Intense
training
of
researchers
in
the
methods
and

techniques
fostering
innova+on

–  effort
to
develop
new
skills

–  effort
to
work
across
disciplines

–  effort
to
interact
with
non-‐researchers

•  A
stronger
dialogue
with
the
policy-‐makers
and
the

Managing
Authority
(not
just
financial
reports
and

online
consulta+ons!)

22
CONCLUSIONS

•  The
aim
of
this
Conference
was
to
assess
the

capacity
of
biomedical
researchers
to
develop

innova+ons.

– Note:
analysis
focussed
on
"Readiness",
not
on

"quality"
of
results,
methods
or
approaches

•  There
is
a
large
poten+al
to
progress
from
the

phase
of
“technological
research”
to
the

phase
of
“technological
developments”
(i.e

from
TRL
3
to
TRL
4-‐6).

23
NEXT
ACTIONS

1.  Conference
proceedings
book
publica+on

2.  Brainstorming
session
of
the
coordinators
of

the
6
projects

–  to
be
scheduled

3.  Organisa+on
of
a
brockerage
event
(June

2014)
involving

–  researchers

–  industries

–  public
bodies

24
THANKS

to
everybody
for
your
par+cipa+on

to
Paola
Storici
–
coorganiser

to
Lucia
Gardossi
-‐
moderator

25
THANKS

to
Divulgando
s.r.l

for
crea+ve
organisa+onal
op+misa+on

website
annoncement
and
management,
conference
material,

pictures,
logis+cs,
post-‐event
follow-‐up

hp://www.units.it/vedinews/index.php?id=4209&+ponews=5

hp://www.ﬂickr.com/photos/trans2care/sets/72157641645322424/

Facts figures and features conference report / CONFERENCE: CROSS-BORDER ITALY-SLOVENIA BIOMEDICAL RESEARCH: ARE WE READY FOR HORIZON 2020?

Recommended

Recommended

More Related Content

What's hot

What's hot (15)

Similar to Facts figures and features conference report / CONFERENCE: CROSS-BORDER ITALY-SLOVENIA BIOMEDICAL RESEARCH: ARE WE READY FOR HORIZON 2020?

Similar to Facts figures and features conference report / CONFERENCE: CROSS-BORDER ITALY-SLOVENIA BIOMEDICAL RESEARCH: ARE WE READY FOR HORIZON 2020? (20)

More from Sabina Passamonti

More from Sabina Passamonti (17)

Facts figures and features conference report / CONFERENCE: CROSS-BORDER ITALY-SLOVENIA BIOMEDICAL RESEARCH: ARE WE READY FOR HORIZON 2020?